Splenocytes from Tcj2 mRNA LNP—Immunized mice decrease <i>T</i>. <i>cruzi</i> infection <i>in vitro</i>. by Leroy Versteeg (4248760)

Number of visits per clinic type, 2013-2015. by Jacob Dreiher (14856863)

“…During PE, statistically significant longer waiting times were found for surgery (+1.0 day) and imaging (+1.1 days), while a 2.4 days decrease was noted in pediatrics, controlled for age, sex, ethnicity and the daily number of visits. …”

Table 1_A novel α-conotoxin [D1G, ΔQ14] LvIC decreased mouse locomotor activity.xls by Wen Wang (6570)

“…</p>Conclusion<p>Our findings indicate that α-conotoxin [D1G, ΔQ14] LvIC significantly decreased locomotor activity in mice. Additionally, it altered gene expression primarily in areas related to neuronal development, synapse formation, and neuron activity, while also reducing synapse strength. …”

Table 2_A novel α-conotoxin [D1G, ΔQ14] LvIC decreased mouse locomotor activity.xls by Wen Wang (6570)

“…</p>Conclusion<p>Our findings indicate that α-conotoxin [D1G, ΔQ14] LvIC significantly decreased locomotor activity in mice. Additionally, it altered gene expression primarily in areas related to neuronal development, synapse formation, and neuron activity, while also reducing synapse strength. …”

Four grid table. by Xiaoling Zhong (181270)

Subjects:

Flowchart depicting the selection of the study population. by Xiaoling Zhong (181270)

Subjects:

Signal strength of reports of finasteride administration at the PT level (age < 18). by Xiaoling Zhong (181270)

Subjects:

Basic information and patient characteristics according to the report. by Xiaoling Zhong (181270)

Subjects:

Signal strength of reports of finasteride administration at the preferred term level in the FAERS database. by Xiaoling Zhong (181270)

Subjects:

Four major algorithms used for signal detection. by Xiaoling Zhong (181270)

Subjects:

Time to onset of AEs in male and female patients receiving finasteride therapy. by Xiaoling Zhong (181270)

Subjects:

Signal strength of reports of finasteride administration at the SOC level. by Xiaoling Zhong (181270)

Subjects:

Signal strength of reports of finasteride administration at the SOC level by Xiaoling Zhong (181270)

Subjects:

Signal strength of reports of finasteride administration in female at the PT level. by Xiaoling Zhong (181270)

Subjects:

Signal strength of reports of finasteride administration in male at the PT level. by Xiaoling Zhong (181270)

Subjects:

Signal strength of reports of finasteride administration at the PT level (age = 18-65). by Xiaoling Zhong (181270)

Subjects:

Signal strength of reports of finasteride administration at the PT level (age>=65). by Xiaoling Zhong (181270)

Subjects:

Clinical characteristics of reports with finasteride as the primary suspected drug from the FAERS database. by Xiaoling Zhong (181270)

Subjects:

Sex-differentiated risk signal volcano plot for finasteride. by Xiaoling Zhong (181270)

Subjects:

Number of adverse reaction case reports of finasteride administration at the PT level. by Xiaoling Zhong (181270)

Subjects: